RHEACELL is dedicated to drug development based on ABCB5-positive (ABCB5+) mesenchymal stem cells as a platform technology. An essential part of RHEACELL's research program is the development of new and innovative therapeutic approaches and the verification of these in clinical trials. The ultimate goal is to provide patients with new therapeutic options for diseases that have so far been untreatable or insufficiently treatable.

Since mid-2016, RHEACELL has been recruiting patients with chronic venous ulcers (CVU) for a Phase I/IIa clinical trial with autologous (patient-derived) ABCB5+ mesenchymal stem cells. Since the end of 2017, RHEACELL is also recruiting patients for clinical trials with allogeneic (donor-derived) ABCB5+ mesenchymal stem cells in Phase I/IIa for the following indications: Chronic venous leg ulcers (CVU), diabetic foot ulcers (DFU) and peripheral arterial occlusive disease (PAD). Since November 2018, RHEACELL is also recruiting patients with recessive dystrophic epidermolysis bullosa (RDEB) for a Phase I/IIa clinical trial with allogeneic (donor-derived) ABCB5+ mesenchymal stem cells. Furthermore, studies in collaboration with various research centers in the areas of limbal stem cell deficiency, liver and kidney regeneration and tumor diseases are being planned.